Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing
Patent
1996-09-11
1999-03-09
Minnifield, Nita
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
4241841, 4242181, 424816, 4241591, 4242771, 4241551, 4241561, 4242781, A61K 39395, A61K 3912, A61K 4500, A01N 6300
Patent
active
058796754
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The invention relates to cancer and viral vaccines
BACKGROUND OF THE INVENTION
The basic rationale for immune therapy against tumors is the induction of an effective immune response against tumor-associated antigens (TAA), which in turn results in immune-mediated destruction of proliferating tumor cells expressing these antigens. For an immune response to be effective against TAAs comprising protein, these antigens must first be endocytosed by macrophages. Within macrophages, TAAs are degraded in the lysosomal compartment and the resulting peptides are expressed on the surface of the macrophage cell membrane in association with MHC Class II molecules. This expression mediates recognition by specific CD4.sup.+ helper T cells and subsequent activation of these cells to effect the immune response (Stevenson, 1991, FASEB J. 5:2250; Lanzavecchia, 1993, Science 260:937; Pardoll, 1993, Immunol. Today 14:310). The majority of human TAA molecules have not been defined in molecular terms and as a consequence, no generic version of these molecules is available for exploitation as a potential anti-tumor vaccine. Attempts to modify autologous tumor cells in each individual patient as a means of eliciting an immune response to TAAs have met with little success. In order for autologous TAA-expressing tumor cells to function as effective vaccines, they must be opsonized in some manner so that their phagocytosis by macrophages is enhanced.
To date, available viral vaccines comprise either infectious, attenuated live virus, non-infectious killed virus or subunits thereof. While live attenuated virus is a more efficacious vaccine than killed virus, vaccines of this type are often genetically unstable and thus, have the potential to revert to a wild type, virulent phenotype. In addition, administration of live attenuated vaccines is contraindicated in immunocompromised individuals and in pregnant women. Non-infectious, killed virus vaccines and vaccines comprising viral subunits also have disadvantages in that they have insufficient immunogenic properties and must be administered in high concentrations at frequent intervals.
Anti-Gal, a naturally occurring antibody present in all humans, specifically interacts with the carbohydrate epitope Gal.alpha.1-3Gal.beta.1-4GlcNAc-R (.alpha.-galactosyl epitope). This antibody does not interact with any other known carbohydrate epitope produced by mammalian cells (Galili, 1993, Springer Seminar Immunopathology 15:153). Anti-Gal constitutes approximately 1% of circulating IgG (Galili et al., 1984, J. Exp. Med. 160:1519) and is also found in the form of IgA and IgM (Davine et al., 1987, Kidney Int. 31:1132; Sandrin et al., 1993, Proc. Natl. Acad. Sci. USA 90:11391). It is produced by 1% of circulating B lymphocytes (Galili et al., 1993, Blood 82:2485).
Both anti-Gal and .alpha.-galactosyl epitope exhibit a unique distribution pattern in mammals. Anti-Gal is *produced abundantly in humans, apes and Old World monkeys, but is absent in New World monkeys, prosimians and non-primate mammals (Galili et al., 1987, Proc. Natl. Acad. Sci. USA 84:1369). In contrast, the .alpha.-galactosyl epitope is found as part of the terminal carbohydrate structure on glycolipids and on carbohydrate chains of glycoproteins, in particular on asparagine (N)-linked carbohydrate chains, in non-primate mammals, prosimians and New World monkeys, but is absent in Old World monkeys, apes and humans (Galili et al., 1987, Proc. Natl. Acad. Sci. USA 84:1369; Galili et al., 1988, J. Biol. Chem. 263:17755).
Asparagine (N)-linked carbohydrate chains similar to those present on mammalian cells, are found attached to envelope glycoproteins of viruses which bud from vertebrate cells (Klenk, 1990, p. 25-37. In: Regenmortel and Neurath (ed.). Immunochemistry of Viruses, II. The Basis for Serodiagnosis and Vaccines. Elsevier Publishers B.V., N.Y.). These carbohydrate chains most often are of the simple high-mannose type containing mannose and N-acetylglucosamine only or of the complex type wherein they co
REFERENCES:
patent: 4008317 (1977-02-01), Gits
Gollogly et al, Neoplasma 43(5):285-89, 1996.
Tremont-Lukats et al, Gynecologic Oncology 64:207-212, 1997.
Galili et al, Vaccine, 14:321-28, 1996.
Gorelik et al, Cancer Res. 57:332-336, 1997.
Qu et al, Glycobiology, 7(6):803-809, 1997.
LaTemple et al, Cancer Res. 56:3069-3074, 1996.
Boduszek et al. J. Med. Chem. 37:3969-76, 1994.
Azadi et al, Glycobiology 5(8):783-789, 1995.
Bystryn, Cancer & Metastasis Rev. 9:81-91, 1990.
Siemann, Rodent Tumor Models in Exptal, Cancer Therapy. Ed. Kallman pp. 12-15, 1987.
Avila, et al. 1989, Journal of Immunology, vol. 142, No. 8, "Immunogenic Gal.alpha. 1--3gal carbohydrate epitopes are present on pathogenic american Trypanosoma and Leishmania", pp. 1818-2834 (15 Apr. 1989).
Galili et al., Proceedings National Academy Sciences USA, vol. 84, "Evolutionary relationship between the natural anti-Gal antibody and the Gal.alpha. 1.fwdarw.3 Gal epitope in primates", pp. 1369-1273 (Mar. 1987).
Galili et al., J Exp. Med., vol. 162, "Human Natural Anti-Galactosyl IgG II. The specific Recognition of .alpha.(1.fwdarw.3)-Linked Galactose Residues", pp. 573-582 (Aug. 1985).
U. Galili, Immunology Today, vol. 14, No. 10, "Interaction of the natural anti-Gal antibody with .alpha.-galactosyl epitopes: a major obstacle for xenotransplantation in humans", pp. 480-482 (1993).
M.S. Sandrin et al., Proceedings National Academy Sciences USA, vol. 90, "Anti-pig IgM antibodies in human serum react predominantly with Gal (.alpha.1-3) Gal epitopes", pp. 11391-11395 (Dec. 1993).
U. Galili et al., Journal of Biological Chemistry, vol. 263, "Man, apes, and Old World Monkey differ from other mammals in the expression of .alpha.-Galactosyl epitopes on nucleated cells" pp. 17755-17762 (25 Nov. 1988).
R.J. Winand et al., Journal of Immunology, vol. 151, No. 7, "Xenogeneic thyroid-stimulating hormone-like activty of the human natural nati-gal antibody", pp. 3923-3934 (01 Oct. 1993).
U. Galili, Immunopathology, vol. 15, "Evolution and pathophysiology of the human natural anti-.alpha.-galactosyl IgG (anti-gal) antibody" pp. 155-171 (1993).
P.M. Repik, Journal of General Virology, "Differential host-dependent expression of .alpha.-galactosyl epitopes on viral glycoproteins: a study of eastern equine encephalitis virus as a model", pp. 1177-1181 (9114).
Basu et al., "Enzymatic Synthesis of Blood Group B-related Pentaglycosylceramide by an .alpha.-Galactosyltransferase from Rabbitt Bone Marrow", J. Biol. Chem. (1973) 248:1700-1706.
Blanken et al., "Biosynthesis of Terminal Gal.alpha.1-3Ga1.beta.1-4GalcNAc-R Oligosaccharide Sequences on Glycoconjugates", J. Biol. Chem. (1985) 260:12927-12934.
Brand et al., "Sequential Passage of Influenza Virus in Embryonated Eggs or Tissue Culture: Emergence of Mutants", Virology (1980) 107:424-433.
Burke et al., "Purification and Composition of the Proteins from Sindbis Virus Grown in Chick and BHK Cells", J. Virol. (1976) 20:676-686.
Chang and Trent, "Nucleotide Sequence of the Genome Region Encoding the 26S mRNA of Eastern Equine Encephalomyelitis Virus and the Deduced Amino Acid Sequence of the Viral Structural Proteins", J. Gen. Virol. (1987) 68:2129-2142.
Chien et al., "Isolation and Characterization of a Heptaglycosylceramide from Bovine Erythrocyte Membranes" , J. Lipid Res. (1979) 20:669-673.
Davin et al., Anti-.alpha.-Galactosyl Antibodies and Immune Complexes in Children With Henoch-Schonlein Purpura or IgA Nephropathy Kidney Int. (1987) 31:1132-1139.
Doerfler, "Expression of the Autographa California Nuclear Polyhedrosis Virus Genome in Insect Cells: Homologous Viral and Heterologous Vertebrate Genes-The Baculovirus Vector System" Curr. Topics Microbiol. Immunol. (1986) 131:51-68.
Egge et al., "Immunochemistry of I/i-active Oligo- and Polyglycosylceramides from Rabbit Erythrocyte Membranes, 1985, J. Biol. Chem.", J. Biol. Chem. (1985) 260:4927-4935.
Elices et al., "Purification and Characterization of a UDP-Gal:.beta.-DGal(1,4)-D-GlcNAc.alpha.(1-3)-Galactosyltransferase
Galili Uri
Repik Patricia M.
Medical College of Pennsylvania and Hahnemann University
Minnifield Nita
LandOfFree
Compositions and methods for vaccines comprising .alpha.-galacto does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for vaccines comprising .alpha.-galacto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for vaccines comprising .alpha.-galacto will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1317896